Molecular Therapy: Oncolytics (Dec 2021)

USMB-shMincle: a virus-free gene therapy for blocking M1/M2 polarization of tumor-associated macrophages

  • Vivian Weiwen Xue,
  • Jeff Yat-Fai Chung,
  • Philip Chiu-Tsun Tang,
  • Alex Siu-Wing Chan,
  • Travis Hoi-Wai To,
  • Justin Shing-Yin Chung,
  • Francis Mussal,
  • Eric W.-F. Lam,
  • Chunjie Li,
  • Ka-Fai To,
  • Kam-Tong Leung,
  • Hui-Yao Lan,
  • Patrick Ming-Kuen Tang

Journal volume & issue
Vol. 23
pp. 26 – 37

Abstract

Read online

Mincle is essential for tumor-associated macrophage (TAM)-driven cancer progression and represents a potential immunotherapeutic target for cancer. Nevertheless, the lack of a specific inhibitor has largely limited its clinical translation. Here, we successfully developed a gene therapeutic strategy for silencing Mincle in a virus-free and tumor-specific manner by combining RNA interference technology with an ultrasound-microbubble-mediated gene transfer system (USMB). We identified a small hairpin RNA (shRNA) sequence shMincle that can silence not only Mincle expression but also the protumoral effector production in mouse bone marrow- and human THP-1-derived macrophages in the cancer setting in vitro. By using our well-established USMB system (USMB-shMincle), the shMincle-expressing plasmids were delivered in a tissue-specific manner into xenografts of human lung carcinoma A549 and melanoma A375 in vivo. Encouragingly, we found that USMB-shMincle effectively inhibited the protumoral phenotypes of TAMs as well as the progression of both A549 and A375 xenografts in a dose-dependent manner in mice without significant side effects. Mechanistically, we identified that USMB-shMincle markedly enhanced the anticancer M1 phenotype of TAMs in the A549 and A375 xenografts by blocking the protumoral Mincle/Syk/nuclear factor κB (NF-κB) signaling axis. Thus, USMB-shMincle may represent a clinically translatable novel and safe gene therapeutic approach for cancer treatment.

Keywords